The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1299
Bendamustine (Treanda) for CLL and NHL
The full article is available to subscribers Subscriber Login   
Correction: In the Clinical Studies section, the complete response rate with chlorambucil for CLL was 2% (not 24%).

Bendamustine HCl (Treanda – Cephalon), an unusual DNA-alkylating agent that has been used in Europe for many years to treat lymphoma, has now been approved by the FDA for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).1,2

CLINICAL STUDIES — CLL – FDA approval of bendamustine for treatment of CLL was apparently based on a single unpublished study of 305 patients with previously untreated B-cell CLL randomized to IV bendamustine or oral chlorambucil (Leukeran). The overall response rate (ORR) was 68% and the complete response (CR) rate was 30% with bendamustine, compared to an ORR of 39% and CR of 2% with chlorambucil.3 Median progression-free survival was 21.7 months with bendamustine vs. 9.3 months with chlorambucil, and median duration of remission was 18.9 months for bendamustine and 6.1 months ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Bendamustine (Treanda) for CLL and NHL
Article code: 1299c
 Electronic, downloadable article - $25